Search

The global rise in obesity and its co-morbidities raises worldwide health, social and economic concerns, especially in developed countries. Compounds derived from natural sources are now in the focus of pharmacological therapies. In recent years, sulforaphane (SFN) has been the subject of studies due to its anti-cancer, anti-inflammatory, antioxidant and potential anti-obesity effects. Lately, some studies have also reported the anti-obesogenic potential of chlorophyll. In this study, we evaluated the anti-obesity effects of SFN and chlorophyll a (Chlo.a) in C57BL/6J mice fed with a Western diet, rich in sugar and fat. The study lasted 14 weeks, and for the last 4 weeks SFN (0.25 or 0.5 mg/kg/day) or Chlo.a (0.2 or 0.5 mg/kg/day) was administered orally. The results showed that supplementation with SFN or Chlo.a resulted in an increase in body temperature and a reduction in the size of adipocytes. However, the administration of SFN or Chlo.a for 4 weeks did not decrease the body weight gain or hepatic steatosis, and increased hepatic ROS counterbalancing with an increase in SOD activity. In conclusion, in the animal model used, treatment with SFN or Chlo.a did not show strong anti-obesity effects; however, slight improvements were observed with the supplementation of these compounds.

Obesity is a disease whose incidence has increased over the last few decades. Despite being a multifactorial disease, obesity results essentially from excessive intake of high-calorie foods associated with low physical activity. The demand for a pharmacological therapy using natural compounds as an alternative to synthetic drugs has increased. Natural compounds may have few adverse effects and high economic impact, as most of them can be extracted from underexploited plant species and food by-products. To test the potential anti-obesogenic effects of new natural substances, the use of preclinical animal models of obesity has been an important tool, among which rat and mouse models are the most used. Some animal models are monogenic, such as the db/db mice, ob/ob mice, Zucker fatty rat and Otsuka Long-Evans Tokushima fatty rat. There are also available chemical models using the neurotoxin monosodium glutamate that induces lesions in the ventromedial hypothalamus nucleus, resulting in the development of obesity. However, the most widely used are the obesity models induced by high-fat diets. The aim of this review was to compile detail studies on the anti-obesity effects of natural compounds or their derivatives on rodent models of obesity as well as a critical analysis of the data.

Obesity, classified as an epidemic by the WHO, is a disease that continues to grow worldwide. Obesity results from abnormal or excessive accumulation of fat and usually leads to the development of other associated diseases, such as type 2 diabetes, hypertension, cancer, cardiovascular diseases, among others. In vitro and in vivo models have been crucial for studying the underlying mechanisms of obesity, discovering new therapeutic targets, and developing and validating new pharmacological therapies against obesity. Preclinical animal models of obesity comprise a variety of species: invertebrates, fishes, and mammals. However, small rodents are the most widely used due to their cost-effectiveness, physiology, and easy genetic manipulation. The induction of obesity in rats or mice can be achieved by the occurrence of spontaneous single-gene mutations or polygenic mutations, by genetic modifications, by surgical or chemical induction, and by ingestion of hypercaloric diets. In this review, we describe some of the most commonly used murine models in obesity research.